<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">nnp</journal-id><journal-title-group><journal-title xml:lang="en">Neurology, Neuropsychiatry, Psychosomatics</journal-title><trans-title-group xml:lang="ru"><trans-title>Неврология, нейропсихиатрия, психосоматика</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2074-2711</issn><issn pub-type="epub">2310-1342</issn><publisher><publisher-name>"IMA-Press", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/2074-2711-2020-5-18-23</article-id><article-id custom-type="elpub" pub-id-type="custom">nnp-1444</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ И МЕТОДИКИ</subject></subj-group></article-categories><title-group><article-title>The quality of prior antithrombotic therapy and the severity of ischemic stroke in atrial fibrillation</article-title><trans-title-group xml:lang="ru"><trans-title>Качество предшествующей антитромботической терапии и тяжесть ишемического инсульта при фибрилляции предсердий</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гераскина</surname><given-names>Л. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Geraskina</surname><given-names>L. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Людмила Александровна Гераскина</p><p> 125367, Москва, Волоколамское шоссе, 80</p><p> </p></bio><bio xml:lang="en"><p>Lyudmila A. Geraskina</p><p>80, Volokolamskoe Shosse, Moscow 125367</p></bio><email xlink:type="simple">neurocor@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алиева</surname><given-names>М. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Alieva</surname><given-names>M. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нервных болезней и нейрохирургии им. Ю.С. Мартынова</p><p>117198, Москва, ул. Миклухо-Маклая, 6 </p></bio><bio xml:lang="en"><p>Yu.S. Martynov Department of Nervous System Diseases and Neurosurgery</p><p>6, Miklukho-Maklai St., Moscow 117198</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Фонякин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Fonyakin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> 125367, Москва, Волоколамское шоссе, 80</p></bio><bio xml:lang="en"><p>80, Volokolamskoe Shosse, Moscow 125367</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Максимова</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Maksimova</surname><given-names>M. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p> 125367, Москва, Волоколамское шоссе, 80</p></bio><bio xml:lang="en"><p>80, Volokolamskoe Shosse, Moscow 125367</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гарабова</surname><given-names>Н. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Garabova</surname><given-names>N. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нервных болезней и нейрохирургии им. Ю.С. Мартынова</p><p>117198, Москва, ул. Миклухо-Маклая, 6 </p></bio><bio xml:lang="en"><p>Yu.S. Martynov Department of Nervous System Diseases and Neurosurgery</p><p>6, Miklukho-Maklai St., Moscow 117198</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Буржунова</surname><given-names>М. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Burzhunova</surname><given-names>M. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кафедра нервных болезней и нейрохирургии им. Ю.С. Мартынова</p><p>117198, Москва, ул. Миклухо-Маклая, 6 </p></bio><bio xml:lang="en"><p>Yu.S. Martynov Department of Nervous System Diseases and Neurosurgery</p><p>6, Miklukho-Maklai St., Moscow 117198</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научный центр неврологии»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Center of Neurology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Медицинский институт ФГАОУ ВО «Российский университет дружбы народов»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Medical Institute, Peoples’ Friendship University of Russia (RUDN University)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2020</year></pub-date><pub-date pub-type="epub"><day>24</day><month>10</month><year>2020</year></pub-date><volume>12</volume><issue>5</issue><fpage>18</fpage><lpage>23</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Geraskina L.A., Alieva M.M., Fonyakin A.V., Maksimova M.Y., Garabova N.I., Burzhunova M.G., 2020</copyright-statement><copyright-year>2020</copyright-year><copyright-holder xml:lang="ru">Гераскина Л.А., Алиева М.М., Фонякин А.В., Максимова М.Ю., Гарабова Н.И., Буржунова М.Г.</copyright-holder><copyright-holder xml:lang="en">Geraskina L.A., Alieva M.M., Fonyakin A.V., Maksimova M.Y., Garabova N.I., Burzhunova M.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://nnp.ima-press.net/nnp/article/view/1444">https://nnp.ima-press.net/nnp/article/view/1444</self-uri><abstract><p>The severity of neurological disorders in ischemic stroke (IS) in the presence of atrial fibrillation (AF) is known to be higher than that in patients with sinus rhythm. The impact of preventive antithrombotic therapy (ATT) on the clinical manifestations and outcomes of stroke remains a matter of debate.</p><sec><title>Objective</title><p>Objective: to analyze the quality of preventive ATT and to clarify its relationship to the severity of IS in AF.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. The data from the registry of patients (n = 200; 96 (48%) men) (mean age, 71±9 years) with IS and AF were analyzed. Neurological deficit at admission was graded using the National Institutes of Health Stroke Scale (NIHSS). The presence and nature of prestroke antithrombotic therapy were studied.</p></sec><sec><title>Results and discussion</title><p>Results and discussion. Prestroke ATT was performed in 80 (40%) patients, of whom 36 (18%) took antiplatelet agents (APAs). Oral anticoagulants (OACs) were given to 44 patients. The international normalized ratio (INR) in the use of vitamin K antagonists (VKAs) averaged 1.26 [1.11; 1.64]. Neurological deficit was most obvious in the patients who had not previously received ATT (a NIHSS score of 8 [5; 12]). In comparison with them, the regular use of ATT, including APAs and OACs, was associated with the greater likelihood of less severe neurological deficit (a NIHSS of &lt;8): odds ratio (OR), 2.121; 95% confidence interval (CI), 1.178–3.820. The greatest decrease in stroke severity was related to direct (OACs) (DOACs): OR, 2.727 (95% CI, 1.049–7.089), while there was no positive effect of VKAs (OR, 1.534; 95% CI, 0.538–4.377), which was associated with failure to achieve the INR target. Improvement was also related to the prescription of APAs (OR, 2.111; 95% CI, 0.981–4.539).</p></sec><sec><title>Conclusion</title><p>Conclusion. Preventive ATT for a significant proportion of AF patients does not meet the current recommendations. At the same time, ATT, especially that with DOACs, is associated with the lesser severity of IS.</p></sec></abstract><trans-abstract xml:lang="ru"><p>Известно, что тяжесть неврологических нарушений при ишемическом инсульте (ИИ) на фоне фибрилляции предсердий (ФП) выше, чем у пациентов с синусовым ритмом. Влияние превентивной антитромботической терапии (АТТ) на клинические проявления и исходы инсульта остается предметом дискуссий.</p><p>Цель исследования – анализ качества превентивной АТТ и уточнение его взаимосвязи с тяжестью ИИ при ФП.</p><sec><title>Пациенты и методы</title><p>Пациенты и методы. Выполнен анализ данных регистра пациентов с ИИ и ФП [n=200, из них 96 (48%) мужчин, средний возраст – 71±9 лет]. Неврологический дефицит при поступлении оценивали по Шкале тяжести инсульта Национальных институтов здоровья CША (NIHSS). Изучали наличие и характер АТТ, предшествовавшей инсульту.</p></sec><sec><title>Результаты и обсуждение</title><p>Результаты и обсуждение. До инсульта АТТ принимали 80 (40%) пациентов, из них 36 (18%) – тромбоцитарные антиагреганты (ААГ). Оральные антикоагулянты (ОАК) получали 44 пациента. Значения международного нормализованного отношения (МНО) на фоне антагонистов витамина К (АВК) в среднем составили 1,26 [1,11; 1,64]. Неврологический дефицит был наиболее выраженным у пациентов, ранее не получавших АТТ: NIHSS 8 [5; 12] баллов. По сравнению с ними регулярный прием АТТ, включая ААГ и ОАК, ассоциировался с увеличением вероятности менее тяжелого неврологического дефицита (NIHSS &lt;8): отношение шансов (ОШ) 2,121; 95% доверительный интервал (ДИ) 1,178–3,820. Наибольшее снижение тяжести инсульта было связано с прямыми ОАК (ПОАК): ОШ 2,727 (95% ДИ 1,049–7,089), тогда как позитивного влияния АВК не отмечено (ОШ 1,534; 95% ДИ 0,538–4,377), что связано с недостижением целевых значений МНО. Улучшение ассоциировалось также с назначением ААГ: ОШ 2,111 (95% ДИ 0,981–4,539).</p></sec><sec><title>Заключение</title><p>Заключение. У значительной части пациентов с ФП превентивная АТТ не соответствует современным рекомендациям. Вместе с тем АТТ, особенно ПОАК, ассоциируется с меньшей тяжестью ИИ.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>ишемический инсульт</kwd><kwd>фибрилляция предсердий</kwd><kwd>антитромботическая терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ischemic stroke</kwd><kwd>atrial fibrillation</kwd><kwd>antithrombotic therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Рекомендации ESC по лечению пациентов с фибрилляцией предсердий, разработанные совместно с EACTS. Российский кардиологический журнал. 2017;7(147):7-86. doi: 10.15829/1560-4071-2017-7-7-86</mixed-citation><mixed-citation xml:lang="en">2016 ESC Guidelines for the Management of atrial fibrillation developed with EACTS. Rossiyskiy kardiologicheskiy zhurnal = Russ J Cardiol. 2017;7(147):7-86. doi: 10.15829/1560-4071-2017-7-7-86 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991 Aug;22(8):983-8. doi: 10.1161/01.str.22.8.983</mixed-citation><mixed-citation xml:lang="en">Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham study. Stroke. 1991 Aug;22(8):983-8. doi: 10.1161/01.str.22.8.983</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Heemstra HE, Nieuwlaat R, Meijboom M, Crijns HJ. The burden of atrial fibrillation in the Netherlands. Neth Heart J. 2011 Sep;19(9):373-8. doi: 10.1007/s12471-011-0175-4</mixed-citation><mixed-citation xml:lang="en">Heemstra HE, Nieuwlaat R, Meijboom M, Crijns HJ. The burden of atrial fibrillation in the Netherlands. Neth Heart J. 2011 Sep;19(9):373-8. doi: 10.1007/s12471-011-0175-4</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ceornodolea AD, Bal R, Severens JL. Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries. Stroke Res Treat. 2017;2017:8593207. doi: 10.1155/2017/8593207. Epub 2017 May 28.</mixed-citation><mixed-citation xml:lang="en">Ceornodolea AD, Bal R, Severens JL. Epidemiology and Management of Atrial Fibrillation and Stroke: Review of Data from Four European Countries. Stroke Res Treat. 2017;2017:8593207. doi: 10.1155/2017/8593207. Epub 2017 May 28.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000 Jan;35(1):183-7. doi: 10.1016/s0735-1097(99)00489-1</mixed-citation><mixed-citation xml:lang="en">Hart RG, Pearce LA, Rothbart RM, et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. 2000 Jan;35(1):183-7. doi: 10.1016/s0735-1097(99)00489-1</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Perera KS, Vanassche T, Bosch J, et al., on behalf of the ESUS Global Registry Investigators. Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke. Embolic Stroke of Undetermined Source Global Registry. Stroke. 2016;47:2197-202. doi: 10.1161/STROKEAHA.116.013378</mixed-citation><mixed-citation xml:lang="en">Perera KS, Vanassche T, Bosch J, et al., on behalf of the ESUS Global Registry Investigators. Global Survey of the Frequency of Atrial Fibrillation-Associated Stroke. Embolic Stroke of Undetermined Source Global Registry. Stroke. 2016;47:2197-202. doi: 10.1161/STROKEAHA.116.013378</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28.</mixed-citation><mixed-citation xml:lang="en">January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS Guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76. doi: 10.1016/j.jacc.2014.03.022. Epub 2014 Mar 28.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016 Nov;18(11):1609- 78. doi: 10.1093/europace/euw295. Epub 2016 Aug 27.</mixed-citation><mixed-citation xml:lang="en">Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016 Nov;18(11):1609- 78. doi: 10.1093/europace/euw295. Epub 2016 Aug 27.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Boussier M-G. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 3:12-9. doi: 10.1159/000209261. Epub 2009 May 14.</mixed-citation><mixed-citation xml:lang="en">Boussier M-G. Antithrombotic agents in the prevention of ischemic stroke. Cerebrovasc Dis. 2009;27 Suppl 3:12-9. doi: 10.1159/000209261. Epub 2009 May 14.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.</mixed-citation><mixed-citation xml:lang="en">Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. doi: 10.1016/S0140-6736(13)62343-0. Epub 2013 Dec 4.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke Severity in Atrial Fibrillation. The Framingham Study. Stroke. 1996 Oct;27(10):1760-4. doi: 10.1161/01.str.27.10.1760</mixed-citation><mixed-citation xml:lang="en">Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke Severity in Atrial Fibrillation. The Framingham Study. Stroke. 1996 Oct;27(10):1760-4. doi: 10.1161/01.str.27.10.1760</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shantsila E, Wolff A, Lip GYH, Lane DA. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. Br J Gen Pract. 2015 Jan;65(630):e16-23. doi: 10.3399/bjgp15X683113</mixed-citation><mixed-citation xml:lang="en">Shantsila E, Wolff A, Lip GYH, Lane DA. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort. Br J Gen Pract. 2015 Jan;65(630):e16-23. doi: 10.3399/bjgp15X683113</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006 Aug;92(8):1064-70. doi: 10.1136/hrt.2005.069492. Epub 2005 Dec 30.</mixed-citation><mixed-citation xml:lang="en">DeWilde S, Carey IM, Emmas C, et al. Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care. Heart. 2006 Aug;92(8):1064-70. doi: 10.1136/hrt.2005.069492. Epub 2005 Dec 30.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hellwig S, Grittner U, Audeberg H, et al. Non-vitamin K-dependent oral anticoagulants have a positive impact on ischemic stroke severity in patients with atrial fibrillation. Europace. 2018 Apr 1;20(4):569-74. doi: 10.1093/europace/eux087</mixed-citation><mixed-citation xml:lang="en">Hellwig S, Grittner U, Audeberg H, et al. Non-vitamin K-dependent oral anticoagulants have a positive impact on ischemic stroke severity in patients with atrial fibrillation. Europace. 2018 Apr 1;20(4):569-74. doi: 10.1093/europace/eux087</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Wang C, Yang Z, Wang C, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry. J Stroke Cerebrovasc Dis. 2014;23(5):1157-63. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.006</mixed-citation><mixed-citation xml:lang="en">Wang C, Yang Z, Wang C, et al. Significant underuse of warfarin in patients with nonvalvular atrial fibrillation: results from the China national stroke registry. J Stroke Cerebrovasc Dis. 2014;23(5):1157-63. doi: 10.1016/j.jstrokecerebrovasdis.2013.10.006</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Переверзева КГ, Мосейчук КА, Воробьев АН и др. Динамика назначения оральных антикоагулянтов амбулаторным пациентам с фибрилляцией предсердий в течение 2012–2016 гг. по данным регистра кардиоваскулярных заболеваний (РЕКВАЗА). Кардиология: Новости, Мнение, Обучение. 2017;(1):44-7.</mixed-citation><mixed-citation xml:lang="en">Pereverzeva KG, Moseichuk KA, Vorobyev AN, et al. Dynamics of prescribing of oral anticoagulants to outpatients with atrial fibrillation during 2012–2016 according to Registry of cardiovascular diseases (REKVAZA). Kardiologiya: Novosti, Mneniye, Obucheniye. 2017;(1):44-7 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Степина ЕВ, Лукьянов ММ, Бичурина МА и др. Терапия оральными антикоагулянтами у больных с фибрилляцией предсердий в сочетании с артериальной гипертонией, ишемической болезнью сердца, хронической сердечной недостаточностью на госпитальном и амбулаторном этапах лечения по данным регистра РЕКВАЗАКЛИНИКА. Рациональная фармакотерапия в кардиологии. 2017;13(2):146-54. doi: 10.20996/1819-6446-20117-13-2-146-154</mixed-citation><mixed-citation xml:lang="en">Stepina EV, Loukianov MM, Bichurina MA, et al. Oral anticoagulants in ambulatory and inhospital treatment of patients with atrial fibrillation associated with hypertension, ischemic heart disease and chronic heart failure: Data from Hospital Registry RECVASA-CLINIC. Ratsional'naya farmakoterapiya v kardiologii = Rational Pharmacotherapy in Cardiology. 2017;13(2):146-54. doi: 10.20996/1819-6446-20117-13-2-146-154 (In Russ).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Le Heuzey J-Y, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation: data from the PREFER IN AF Registry. Thromb Haemost. 2014;111(5):833- 41. doi: 10.1160/TH13-12-1007</mixed-citation><mixed-citation xml:lang="en">Le Heuzey J-Y, Ammentorp B, Darius H, et al. Differences among western European countries in anticoagulation management of atrial fibrillation: data from the PREFER IN AF Registry. Thromb Haemost. 2014;111(5):833- 41. doi: 10.1160/TH13-12-1007</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia Escriva A, Lopez Hernandez N, Hernandez Lorido R, et al. Modification of clinical profile of stroke in atrial fibrillation patients. Effect of antithrombotic treatment. Rev Neurol. 2004 Mar 1-15;38(5):401-5.</mixed-citation><mixed-citation xml:lang="en">Garcia Escriva A, Lopez Hernandez N, Hernandez Lorido R, et al. Modification of clinical profile of stroke in atrial fibrillation patients. Effect of antithrombotic treatment. Rev Neurol. 2004 Mar 1-15;38(5):401-5.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sakamoto Y, Okubo S, Nito C, et al. Insufficient warfarin therapy is associated with higher severity of stroke than no anticoagulation in patients with atrial fibrillation and acute anterior-circulation stroke. Circ J. 2018 Apr 25;82(5):1437-42. doi: 10.1253/circj.CJ-17-1110. Epub 2017 Dec 21.</mixed-citation><mixed-citation xml:lang="en">Sakamoto Y, Okubo S, Nito C, et al. Insufficient warfarin therapy is associated with higher severity of stroke than no anticoagulation in patients with atrial fibrillation and acute anterior-circulation stroke. Circ J. 2018 Apr 25;82(5):1437-42. doi: 10.1253/circj.CJ-17-1110. Epub 2017 Dec 21.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Sakamoto Y, Okubo S, Sekine T, et al. Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation. J Am Heart Assoc. 2018 Sep 4;7(17):e009507. doi: 10.1161/JAHA.118.009507</mixed-citation><mixed-citation xml:lang="en">Sakamoto Y, Okubo S, Sekine T, et al. Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation. J Am Heart Assoc. 2018 Sep 4;7(17):e009507. doi: 10.1161/JAHA.118.009507</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Schwammenthal Y, Bornstein N, Schwammenthal E, et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Am J Cardiol. 2010 Feb 1;105(3):411-6. doi: 10.1016/j.amjcard.2009.09.050. Epub 2009 Dec 22.</mixed-citation><mixed-citation xml:lang="en">Schwammenthal Y, Bornstein N, Schwammenthal E, et al. Relation of effective anticoagulation in patients with atrial fibrillation to stroke severity and survival (from the National Acute Stroke Israeli Survey [NASIS]). Am J Cardiol. 2010 Feb 1;105(3):411-6. doi: 10.1016/j.amjcard.2009.09.050. Epub 2009 Dec 22.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
